{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:52:02Z","timestamp":1793656322982,"version":"4.5.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.bmcl.2017.06.037","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T00:47:34Z","timestamp":1497574054000},"page":"3243-3248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors"],"prefix":"10.1016","volume":"27","author":[{"given":"Christopher M.","family":"Yates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Garvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy R.","family":"Shaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Schotzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2017.06.037_b0005","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2017.06.037_b0010","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.bmcl.2014.04.024","article-title":"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors","volume":"24","author":"Rafferty","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2017.06.037_b0015","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1073\/pnas.061562898","article-title":"Crystal structure of cytochrome P450 14\u03b1-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors","volume":"98","author":"Podust","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.06.037_b0020","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/14728214.2011.607811","article-title":"Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations","volume":"16","author":"Pitman","year":"2011","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.bmcl.2017.06.037_b0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmcl.2017.06.037_b0030","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.06.037_b0035","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/313757","article-title":"Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America","volume":"30","author":"Saag","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2017.06.037_b0040","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/cid\/ciw538","article-title":"Executive summary: 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2017.06.037_b0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bmcl.2017.06.037_b0050","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1684\/ejd.2010.0910","article-title":"Chronic mucocutaneous candidiasis, from bench to bedside","volume":"20","author":"Eyerich","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.bmcl.2017.06.037_h0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/07391102.2004.10506984","volume":"22","author":"Sheng","year":"2004","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.bmcl.2017.06.037_h0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10822-005-3692-7","volume":"19","author":"Rupp","year":"2005","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmcl.2017.06.037_h0065","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.01630-08","volume":"53","author":"Sheng","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2017.06.037_h0070","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cmdc.200900468","volume":"5","author":"Sheng","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2017.06.037_b0070","unstructured":"RCSB Protein Data Bank http:\/\/www.rcsb.org\/pdb\/home."},{"key":"10.1016\/j.bmcl.2017.06.037_b0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bmcl.2005.09.031","article-title":"Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]","volume":"16","author":"Bennett","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2017.06.037_b0085","doi-asserted-by":"crossref","first-page":"25582","DOI":"10.1074\/jbc.M110.133215","article-title":"Structural insights into inhibition of sterol 14\u03b1-demethylase in the human pathogen Trypanosoma cruzi","volume":"285","author":"Lepesheva","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2017.06.037_b0090","unstructured":"Hoekstra WJ, Yates CM. PCT Int. Appl. 2013, WO2013090210."},{"key":"10.1016\/j.bmcl.2017.06.037_b0105","doi-asserted-by":"crossref","unstructured":"Hargrove T, Garvey EP, Hoekstra WJ, et al. Crystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14\u03b1-demethylase provides insights into its broad-spectrum antifungal activity. Antimicrob Agents Chemother Doi: http:\/\/dx.doi.org\/10.1128\/AAC.00570-17 (accepted manuscript).","DOI":"10.1128\/AAC.00570-17"},{"key":"10.1016\/j.bmcl.2017.06.037_b0120","unstructured":"Shubitz LF, Trinh H, Roy M, et al. Novel CYP51 inhibitors for the treatment of Coccidioidomycosis. In: The Proceedings of the 60th Annual Coccidioidomycosis Study Group, April 9; 2016:45."},{"key":"10.1016\/j.bmcl.2017.06.037_b0125","unstructured":"Garvey EP, Sharp AD, Warn PA, Wiederhold NP, Yates CM, Schotzinger RJ. VT-1598 is a highly potent inhibitor of Cryptococcus spp. in vitro and in vivo. In: 10th International Conference on Cryptococcus and Cryptococcosis, March 26\u201330; 2017."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X1730639X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X1730639X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:20:53Z","timestamp":1760772053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X1730639X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":21,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0960894X1730639X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2017.06.037","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2017.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}